Your shopping cart is currently empty

RI-OR2 is a retro-inverso peptide that acts as an amyloid-β (Aβ) oligomerization inhibitor. It binds to fixed β-Amyloid (1-42) monomers and fibrils, with an apparent Kd of 9-12 μM, and also serves as an inhibitor of Aβ(1-42) fibril extension.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | RI-OR2 is a retro-inverso peptide that acts as an amyloid-β (Aβ) oligomerization inhibitor. It binds to fixed β-Amyloid (1-42) monomers and fibrils, with an apparent Kd of 9-12 μM, and also serves as an inhibitor of Aβ(1-42) fibril extension. |
| In vitro | RI-OR2 significantly counteracts the toxicity of Aβ(1-42) on cultured SH-SY5Y neuroblastoma cells [1]. |
| Molecular Weight | 1120.35 |
| Formula | C53H85N17O10 |
| Cas No. | 1219627-58-3 |
| Smiles | [C@H](CC1=CC=CC=C1)(NC([C@@H](CC2=CC=CC=C2)NC(CNC([C@@H](CCCNC(=N)N)NC(C)=O)=O)=O)=O)C(N[C@@H](C(N[C@@H](C(N[C@@H](C(NCC(N[C@H](CCCNC(=N)N)C(N)=O)=O)=O)CCCCN)=O)CC(C)C)=O)[C@H](C)C)=O |
| Sequence | Ac-{d-Arg}-Gly-{d-Phe}-{d-Phe}-{d-Val}-{d-Leu}-{d-Lys}-Gly-{d-Arg}-NH2 |
| Sequence Short | {d-Arg}-G-{d-Phe}-{d-Phe}-{d-Val}-{d-Leu}-{d-Lys}-G-{d-Arg} |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.